← Leaderboards
Lawrence Fong
University Of California, San Francisco
$19,816,074
Attributed
$25,800,901
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,800,901 · 13
By mechanism
R01$10,753,990 · 7
U01$8,365,965 · 2
R35$4,773,463 · 1
P50$1,041,669 · 1
K23$499,304 · 1
P30$366,510 · 1
Top collaborators
- Eliezer M Van Allen5 shared
- Rahul Aggarwal4 shared
- Michael John Evans4 shared
- Robert H Blelloch3 shared
- Charles Scott Craik3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Michael John Evans$10,372,266
- Rahul Aggarwal$5,953,056
- Thomas Hope$3,566,163
- Felix Yi-Chung Feng$6,764,664
- Charles Scott Craik$31,131,909
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorImmuneT-LymphocyteResponseImmunotherapyImmune ResponseCancer PatientCellsMalignant NeoplasmsImmunologicsBaseAntigensMalignant Neoplasm Of ProstateFutureResistanceImmune Checkpoint InhibitorBloodProteinsMediatingMouse ModelImmunotherapeutic AgentImmune SystemNeoplastic CellClinical Trials
Grant awards (50)
Determinants of response to cancer immunotherapy$1,055,838
R35 · FY2025 · CA · contact PI
Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer$529,989
P50 · FY2025 · CA · contact PI
Determinants of response to cancer immunotherapy$1,002,984
R35 · FY2024 · CA · contact PI
Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer$511,680
P50 · FY2024 · CA · contact PI
Cancer Immunology and Immunotherapy Program$183,261
P30 · FY2024 · CA · contact PI
Determinants of response to cancer immunotherapy$949,572
R35 · FY2023 · CA · contact PI
Combining immunotherapy with molecularly targeted radiation therapy$663,343
R01 · FY2023 · CA · contact PI
Precision targeting of T cell cytotoxicity with PET$635,683
R01 · FY2023 · CA
Cancer Immunology and Immunotherapy Program$183,249
P30 · FY2023 · CA · contact PI
Determinants of response to cancer immunotherapy$949,572
R35 · FY2022 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$844,999
U01 · FY2022 · CA
Precision targeting of T cell cytotoxicity with PET$652,933
R01 · FY2022 · CA
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression$39,956
U01 · FY2022 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$845,000
U01 · FY2021 · CA
Determinants of response to cancer immunotherapy$815,497
R35 · FY2021 · CA · contact PI
Precision targeting of T cell cytotoxicity with PET$524,205
R01 · FY2021 · CA
Determinants of prostate cancer sensitivity to PD-1 blockade$368,288
R01 · FY2021 · CA · contact PI
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression$155,680
U01 · FY2021 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$844,999
U01 · FY2020 · CA
Mechanisms of Exosome Driven Immunoregulation of Cancer Progression$3,950,956
U01 · FY2019 · CA
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$842,916
U01 · FY2019 · CA
Determinants of prostate cancer sensitivity to PD-1 blockade$355,574
R01 · FY2019 · CA · contact PI
Immunotherapy of human bladder cancer$351,691
R01 · FY2019 · CA · contact PI
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer$841,459
U01 · FY2018 · CA
Determinants of prostate cancer sensitivity to PD-1 blockade$365,428
R01 · FY2018 · CA · contact PI
Immunotherapy of human bladder cancer$362,569
R01 · FY2018 · CA · contact PI
Immunotherapy of human bladder cancer$158,500
R01 · FY2018 · CA · contact PI
Immunotherapy of human bladder cancer$362,569
R01 · FY2017 · CA · contact PI
Immunotherapy of human bladder cancer$158,500
R01 · FY2017 · CA · contact PI
Prostatitis and Prostate Cancer Development$414,029
R01 · FY2016 · CA · contact PI
Immunotherapy of human bladder cancer$362,569
R01 · FY2016 · CA · contact PI
Prostatitis and Prostate Cancer Development$414,029
R01 · FY2015 · CA · contact PI
Immunotherapy of human bladder cancer$362,569
R01 · FY2015 · CA · contact PI
Prostatitis and Prostate Cancer Development$401,608
R01 · FY2014 · CA · contact PI
Prostatitis and Prostate Cancer Development$389,187
R01 · FY2013 · CA · contact PI
Prostate Cancer Immunotherapy$292,312
R01 · FY2013 · CA · contact PI
Prostatitis and Prostate Cancer Development$414,029
R01 · FY2012 · CA · contact PI
Prostate Cancer Immunotherapy$310,970
R01 · FY2012 · CA · contact PI
Prostate Cancer Immunotherapy$310,970
R01 · FY2011 · CA · contact PI
Prostate Cancer Immunotherapy$320,588
R01 · FY2010 · CA · contact PI
Prostate Cancer Immunotherapy$320,588
R01 · FY2009 · CA · contact PI
Dendritics Cell Immunotherapy for Colorectal Cancer$288,476
R01 · FY2008 · CA · contact PI
Dendritics Cell Immunotherapy for Colorectal Cancer$288,476
R01 · FY2007 · CA · contact PI
Dendritics Cell Immunotherapy for Colorectal Cancer$297,092
R01 · FY2006 · CA · contact PI
Dendritics Cell Immunotherapy for Colorectal Cancer$304,241
R01 · FY2005 · CA
Dendritics Cell Immunotherapy for Colorectal Cancer$302,974
R01 · FY2004 · CA
DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER$124,826
K23 · FY2003 · CA
DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER$124,826
K23 · FY2002 · CA
DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER$124,826
K23 · FY2001 · CA
DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER$124,826
K23 · FY2000 · CA